{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:36:03Z","timestamp":1777322163444,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"\"Pioneer\" and \"Leading Goose\" R&D Program of Zhejiang","award":["2022C03046"],"award-info":[{"award-number":["2022C03046"]}]},{"name":"\"Pioneer\" and \"Leading Goose\" R&D Program of Zhejiang","award":["2022C03046"],"award-info":[{"award-number":["2022C03046"]}]},{"name":"\"Pioneer\" and \"Leading Goose\" R&D Program of Zhejiang","award":["2022C03046"],"award-info":[{"award-number":["2022C03046"]}]},{"DOI":"10.13039\/501100017594","name":"Medical and Health Science and Technology Project of Zhejiang Province","doi-asserted-by":"crossref","award":["2019KY117"],"award-info":[{"award-number":["2019KY117"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100017594","name":"Medical and Health Science and Technology Project of Zhejiang Province","doi-asserted-by":"crossref","award":["2022KY230"],"award-info":[{"award-number":["2022KY230"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Project of Zhejiang Chinese Medical University","award":["2022JKJNTZ19"],"award-info":[{"award-number":["2022JKJNTZ19"]}]},{"name":"Research Project of Zhejiang Chinese Medical University","award":["2021JKGJYY007"],"award-info":[{"award-number":["2021JKGJYY007"]}]},{"name":"Research Project of Zhejiang Chinese Medical University","award":["2021JKGJYY007"],"award-info":[{"award-number":["2021JKGJYY007"]}]},{"name":"Research Project of Zhejiang Chinese Medical University","award":["2021JKGJYY007"],"award-info":[{"award-number":["2021JKGJYY007"]}]},{"name":"Research Project of Zhejiang Chinese Medical University","award":["2021JKGJYY007"],"award-info":[{"award-number":["2021JKGJYY007"]}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LSY19H180003"],"award-info":[{"award-number":["LSY19H180003"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LSY19H180003"],"award-info":[{"award-number":["LSY19H180003"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82102128"],"award-info":[{"award-number":["82102128"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The treatment and prognosis of lung adenocarcinoma (LUAD) remains a challenge. The study aimed to conduct a systematic analysis of the predictive capacity of N6-methyladenosine (m6A)-related long non-coding RNAs (lncRNAs) in the prognosis of LUAD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>594 samples were totally selected from a dataset from The Cancer Genome Atlas. The identification of prognostic m6A-related lncRNAs were performed by Pearson correlation analysis and Cox regression analysis. Systematic analyses, including cluster analysis, survival analysis, and immuno-correlated analysis, were conducted. A prognosis model was built from the optimized subset of m6A-related lncRNAs. The assessment of model was performed by survival analysis, and receiver operating characteristic (ROC) curve. Finally, the risk score of patients with LUAD calculated by the prognosis model was implemented by the analysis of Cox regression. Differential analysis was for further evaluation of the cuproptosis-related genes in two risk sets.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>These patients were grouped into two clusters according to the expression levels of 22 prognostic m6A-related lncRNAs. The patients with LUAD in cluster 2 was significantly worse in the overall survival (OS) (<jats:italic>P<\/jats:italic>\u2009=\u20090.006). Three scores calculated by the ESTIMATE methods in cluster 2 were significantly lower. After the least absolute shrinkage and selection operator algorithm, 10 prognostic m6A-related lncRNAs were totally selected to construct the final model to obtain the risk score. Then the area under the ROC curve of the prognosis model for 1, 3, and 5-year OS was 0.767, 0.709, and 0.736 in the training set, and 0.707, 0.691, and 0.675 in the test set. The OS of the low-risk cohort was significantly higher than that of the high-risk cohort in both the training set (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and test set (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). After the analysis of Cox regression, the risk score [Hazard ratio (HR)\u2009=\u20095.792; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001] and stage (HR\u2009=\u20091.576; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) were both considered as independent indicators of prognosis for LUAD. The expression levels of five cuproptosis-related genes were significantly different in two risk sets.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The study constructed a predictive model for the OS of patients with LUAD and these OS-related m6A-lncRNAs might have potential roles in LUAD progression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-022-04869-7","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T08:03:37Z","timestamp":1659945817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis"],"prefix":"10.1186","volume":"23","author":[{"given":"Chen","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuzhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maosheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"issue":"1","key":"4869_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21654.","journal-title":"CA Cancer J Clin"},{"issue":"10125","key":"4869_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(17)33326-3.","journal-title":"Lancet"},{"issue":"7689","key":"4869_CR3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446\u201354. https:\/\/doi.org\/10.1038\/nature25183.","journal-title":"Nature"},{"issue":"7","key":"4869_CR4","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.cell.2019.05.013","volume":"177","author":"JJ Lee","year":"2019","unstructured":"Lee JJ, Park S, Park H, et al. Tracing oncogene rearrangements in the mutational history of lung adenocarcinoma. Cell. 2019;177(7):1842-57.e21. https:\/\/doi.org\/10.1016\/j.cell.2019.05.013.","journal-title":"Cell"},{"issue":"10066","key":"4869_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299\u2013311. https:\/\/doi.org\/10.1016\/S0140-6736(16)30958-8.","journal-title":"Lancet"},{"issue":"13","key":"4869_CR6","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1101\/gad.262766.115","volume":"29","author":"Y Yue","year":"2015","unstructured":"Yue Y, Liu J, He C. RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation. Genes Dev. 2015;29(13):1343\u201355. https:\/\/doi.org\/10.1101\/gad.262766.115.","journal-title":"Genes Dev"},{"issue":"7481","key":"4869_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature12730","volume":"505","author":"X Wang","year":"2014","unstructured":"Wang X, Lu Z, Gomez A, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117\u201320. https:\/\/doi.org\/10.1038\/nature12730.","journal-title":"Nature"},{"issue":"4","key":"4869_CR8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.gendis.2020.03.005","volume":"7","author":"RZ He","year":"2020","unstructured":"He RZ, Jiang J, Luo DX. The functions of N6-methyladenosine modification in lncRNAs. Genes Dis. 2020;7(4):598\u2013605. https:\/\/doi.org\/10.1016\/j.gendis.2020.03.005.","journal-title":"Genes Dis"},{"issue":"6","key":"4869_CR9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41422-018-0040-8","volume":"28","author":"Y Yang","year":"2018","unstructured":"Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018;28(6):616\u201324. https:\/\/doi.org\/10.1038\/s41422-018-0040-8.","journal-title":"Cell Res"},{"issue":"3","key":"4869_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3390\/genes12030440","volume":"12","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Wang M, Zhou J, Dong H, Wang S, Xu H. The important role of N6-methyladenosine RNA modification in non-small cell lung cancer. Genes (Basel). 2021;12(3):440. https:\/\/doi.org\/10.3390\/genes12030440.","journal-title":"Genes (Basel)"},{"key":"4869_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.622233","volume":"12","author":"H Wang","year":"2021","unstructured":"Wang H, Zhao X, Lu Z. m6A RNA methylation regulators act as potential prognostic biomarkers in lung adenocarcinoma. Front Genet. 2021;12: 622233. https:\/\/doi.org\/10.3389\/fgene.2021.622233.","journal-title":"Front Genet"},{"key":"4869_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa225","author":"Y Li","year":"2020","unstructured":"Li Y, Gu J, Xu F, et al. Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma. Brief Bioinform. 2020. https:\/\/doi.org\/10.1093\/bib\/bbaa225.","journal-title":"Brief Bioinform"},{"issue":"5","key":"4869_CR13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41590-020-0650-4","volume":"21","author":"Z Shulman","year":"2020","unstructured":"Shulman Z, Stern-Ginossar N. The RNA modification N6-methyladenosine as a novel regulator of the immune system. Nat Immunol. 2020;21(5):501\u201312. https:\/\/doi.org\/10.1038\/s41590-020-0650-4.","journal-title":"Nat Immunol"},{"issue":"5","key":"4869_CR14","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1002\/jcp.30136","volume":"236","author":"R Xu","year":"2021","unstructured":"Xu R, Pang G, Zhao Q, et al. The momentous role of N6-methyladenosine in lung cancer. J Cell Physiol. 2021;236(5):3244\u201356. https:\/\/doi.org\/10.1002\/jcp.30136.","journal-title":"J Cell Physiol"},{"issue":"2","key":"4869_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","volume":"22","author":"L Statello","year":"2021","unstructured":"Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96\u2013118. https:\/\/doi.org\/10.1038\/s41580-020-00315-9.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"4869_CR16","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/s41467-020-14802-2","volume":"11","author":"Y Li","year":"2020","unstructured":"Li Y, Jiang T, Zhou W, et al. Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers. Nat Commun. 2020;11(1):1000. https:\/\/doi.org\/10.1038\/s41467-020-14802-2.","journal-title":"Nat Commun"},{"issue":"8","key":"4869_CR17","doi-asserted-by":"publisher","first-page":"5600","DOI":"10.1111\/jcmm.14458","volume":"23","author":"A Salavaty","year":"2019","unstructured":"Salavaty A, Rezvani Z, Najafi A. Survival analysis and functional annotation of long non-coding RNAs in lung adenocarcinoma. J Cell Mol Med. 2019;23(8):5600\u201317. https:\/\/doi.org\/10.1111\/jcmm.14458.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"4869_CR18","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3934\/mbe.2020083","volume":"17","author":"Y Ding","year":"2019","unstructured":"Ding Y, Liu JH. The signature lncRNAs associated with the lung adenocarcinoma patients prognosis. Math Biosci Eng. 2019;17(2):1593\u2013603. https:\/\/doi.org\/10.3934\/mbe.2020083.","journal-title":"Math Biosci Eng"},{"key":"4869_CR19","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.omtn.2021.04.003","volume":"24","author":"F Xu","year":"2021","unstructured":"Xu F, Huang X, Li Y, Chen Y, Lin L. m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD. Mol Ther Nucl Acids. 2021;24:780\u201391. https:\/\/doi.org\/10.1016\/j.omtn.2021.04.003.","journal-title":"Mol Ther Nucl Acids"},{"issue":"1","key":"4869_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12943-022-01508-w","volume":"21","author":"L Liu","year":"2022","unstructured":"Liu L, Li H, Hu D, et al. Insights into N6-methyladenosine and programmed cell death in cancer. Mol Cancer. 2022;21(1):32. https:\/\/doi.org\/10.1186\/s12943-022-01508-w.","journal-title":"Mol Cancer"},{"issue":"6586","key":"4869_CR21","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254\u201361. https:\/\/doi.org\/10.1126\/science.abf0529.","journal-title":"Science"},{"key":"4869_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00653-7","author":"D Tang","year":"2022","unstructured":"Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res. 2022. https:\/\/doi.org\/10.1038\/s41422-022-00653-7.","journal-title":"Cell Res"},{"issue":"2","key":"4869_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41568-021-00417-2","volume":"22","author":"EJ Ge","year":"2022","unstructured":"Ge EJ, Bush AI, Casini A, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2022;22(2):102\u201313. https:\/\/doi.org\/10.1038\/s41568-021-00417-2.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"4869_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137. https:\/\/doi.org\/10.1038\/nmeth.3337.","journal-title":"Nat Methods"},{"key":"4869_CR25","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https:\/\/doi.org\/10.1038\/ncomms3612.","journal-title":"Nat Commun"},{"issue":"1","key":"4869_CR26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12943-019-1106-z","volume":"18","author":"T Lan","year":"2019","unstructured":"Lan T, Li H, Zhang D, et al. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3. Mol Cancer. 2019;18(1):186. https:\/\/doi.org\/10.1186\/s12943-019-1106-z.","journal-title":"Mol Cancer"},{"issue":"1","key":"4869_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12943-020-1146-4","volume":"19","author":"X Yang","year":"2020","unstructured":"Yang X, Zhang S, He C, et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol Cancer. 2020;19(1):46. https:\/\/doi.org\/10.1186\/s12943-020-1146-4.","journal-title":"Mol Cancer"},{"issue":"1","key":"4869_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-019-1079-y","volume":"18","author":"W Ni","year":"2019","unstructured":"Ni W, Yao S, Zhou Y, et al. Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m6A reader YTHDF3. Mol Cancer. 2019;18(1):143. https:\/\/doi.org\/10.1186\/s12943-019-1079-y.","journal-title":"Mol Cancer"},{"issue":"8","key":"4869_CR29","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/carcin\/bgy069","volume":"39","author":"M Giulietti","year":"2018","unstructured":"Giulietti M, Righetti A, Principato G, Piva F. LncRNA co-expression network analysis reveals novel biomarkers for pancreatic cancer. Carcinogenesis. 2018;39(8):1016\u201325. https:\/\/doi.org\/10.1093\/carcin\/bgy069.","journal-title":"Carcinogenesis"},{"issue":"7","key":"4869_CR30","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s11626-019-00372-1","volume":"55","author":"J Yang","year":"2019","unstructured":"Yang J, Wu W, Wu M, Ding J. Long noncoding RNA ADPGK-AS1 promotes cell proliferation, migration, and EMT process through regulating miR-3196\/OTX1 axis in breast cancer. In Vitro Cell Dev Biol Anim. 2019;55(7):522\u201332. https:\/\/doi.org\/10.1007\/s11626-019-00372-1.","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"4869_CR31","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3389\/fcell.2020.00642","volume":"8","author":"Z Tu","year":"2020","unstructured":"Tu Z, Wu L, Wang P, et al. N6-Methylandenosine-related lncRNAs are potential biomarkers for predicting the overall survival of lower-grade glioma patients. Front Cell Dev Biol. 2020;8:642. https:\/\/doi.org\/10.3389\/fcell.2020.00642.","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"4869_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.714697","volume":"20","author":"J Zhao","year":"2021","unstructured":"Zhao J, Lin X, Zhuang J, He F. Relationships of N6-methyladenosine-related long non-coding RNAs with tumor immune microenvironment and clinical prognosis in lung adenocarcinoma. Front Genet. 2021;20(12): 714697. https:\/\/doi.org\/10.3389\/fgene.2021.714697 (PMID:34777460;PMCID:PMC8585518).","journal-title":"Front Genet"},{"issue":"11","key":"4869_CR33","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jamaoncol.2017.1609","volume":"3","author":"B Li","year":"2017","unstructured":"Li B, Cui Y, Diehn M, Li R. Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol. 2017;3(11):1529\u201337. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1609.","journal-title":"JAMA Oncol"},{"issue":"16","key":"4869_CR34","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1002\/cam4.3240","volume":"9","author":"S Sun","year":"2020","unstructured":"Sun S, Guo W, Wang Z, et al. Development and validation of an immune-related prognostic signature in lung adenocarcinoma. Cancer Med. 2020;9(16):5960\u201375. https:\/\/doi.org\/10.1002\/cam4.3240.","journal-title":"Cancer Med"},{"issue":"11","key":"4869_CR35","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1016\/j.jtho.2019.07.031","volume":"14","author":"C Zhang","year":"2019","unstructured":"Zhang C, Zhang J, Xu FP, et al. Genomic landscape and immune microenvironment features of preinvasive and early invasive lung adenocarcinoma. J Thorac Oncol. 2019;14(11):1912\u201323. https:\/\/doi.org\/10.1016\/j.jtho.2019.07.031.","journal-title":"J Thorac Oncol"},{"issue":"17","key":"4869_CR36","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1507643.","journal-title":"N Engl J Med"},{"issue":"2","key":"4869_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1504627.","journal-title":"N Engl J Med"},{"issue":"21","key":"4869_CR38","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1501824.","journal-title":"N Engl J Med"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-022-04869-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-022-04869-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-022-04869-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T08:03:51Z","timestamp":1659945831000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-022-04869-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4869"],"URL":"https:\/\/doi.org\/10.1186\/s12859-022-04869-7","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"assertion":[{"value":"28 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TCGA belongs to public databases. The patients involved in the database have obtained ethical approval. Users can download relevant data for free for research and publish relevant articles. Our study is based on open access data, so there are no ethical issues and other conflicts of interest. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"327"}}